OrsoBio

Business news, market intelligence, and global industry analysis.

The Latest

Can fewer infusions improve adherence in Fabry disease enzyme replacement therapy?

CVS stock slips as Aetna settles Medicare Advantage diagnosis code fraud case for $117.7m

What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)

CVGI surges 54% as CVG names Zoox strategic supplier and issues $700M revenue outlook for 2026

OrsoBio unveils ADA 2025 preclinical data showcasing dual-pathway obesity drug strategy with lean mass preservation

OrsoBio presents ADA 2025 data on TLC-6740 and TLC-1180 showing sustained fat loss and lean mass preservation in obesity models. Human trials underway.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

June 25, 2025